IFNA1 and neoplasm: Collectively, combination treatment with 9MU IFN-α s.c. three times a week and 10 mg atrasentan orally once daily is tolerated and our data tentatively indicate the notion that this combination might induce a more indolent course of disease, possibly contributed by additive and/or synergistic anti-tumour effects of both the agents.